23 articles for MW Martin
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Purinylpyridinylamino-based DFG-in/aC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling.

Amgen
Structure-Based Design of Potent and Selective CK1¿ Inhibitors.

TBA
2-Phenylamino-6-cyano-1H-benzimidazole-based isoform selective casein kinase 1 gamma (CK1¿) inhibitors.

Amgen
Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.

Amgen
Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.

Amgen
Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.

Amgen
Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.

Amgen
Discovery of alpha-amidosulfones as potent and selective agonists of CB2: synthesis, SAR, and pharmacokinetic properties.

Amgen
Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2.

Amgen
Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: development of an expedient and divergent synthetic route and preliminary SAR.

Amgen
Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.

Amgen
Discovery and optimization of novel piperazines as potent inhibitors of fatty acid synthase (FASN).

Forma Therapeutics
Design and Optimization of Benzopiperazines as Potent Inhibitors of BET Bromodomains.

Forma Therapeutics
Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11.

Forma Therapeutics
2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF

Guangzhou Salustier Biosciences
Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof

Nurix Therapeutics
Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors

Fedora Pharmaceuticals
The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.

Fred Hutchinson Cancer Research Center
Substituted pyrrolizine compounds and uses thereof

Gilead Sciences
2,4-diaminopyrimidine derivatives as histamine H4 modulators

Janssen Pharmaceutica
Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy

Abbvie Deutschland
Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy

Abbvie Deutschland